Document:

Exhibit
10.6

 

REGISTRATION
RIGHTS AGREEMENT

 

This
Registration Rights Agreement (this “Agreement”) is made and entered into as of August 7, 2020, by and
among Mateon Therapeutics, Inc. (the “Company”), a Delaware corporation with offices at 20397 Agoura Road,
Suite 107, Agoura Hills, California 91301, and the investors signatories hereto (each a “Purchaser” and collectively,
the “Purchasers”). This Agreement is made pursuant to the Subscription Agreement and Investment Letter, dated
as of the date hereof, executed by each of the Purchasers and the Company (the “Subscription Agreement”).

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration
the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers agree as follows:

 

1.
Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Subscription Agreement shall
have the meanings given such terms in the Subscription Agreement. As used in this Agreement, the following terms shall have the
respective meanings set forth in this Section 1.

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 144.

 

“Business
Day” means any day except Saturday, Sunday and any day that shall be a federal legal holiday or a day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Commission”
means the Securities and Exchange Commission.

 

“Company’s
Common Stock” means the Company’s common stock, $0.01 par value per share.

 

“EdgePoint”
means EdgePoint AI, Inc., a EdgePoint corporation that is a wholly owned subsidiary of the Company.

 

“EdgePoint’s
Common Stock” means EdgePoint’s common stock, $0.001 par value per share.

 

“Effective
Date” means the date that the Registration Statement filed pursuant to Section 2(a) is first declared effective
by the Commission.

 

“Effectiveness
Date” means: (a) with respect to the initial Registration Statement required to be filed to cover the resale by the
Holders of the Registrable Securities, the earlier of:

 

(i)
the 120th day following the final Closing Date if the Commission does not review the Registration Statement or (ii) 150 days following
the final Closing Date if the Commission reviews the Registration Statement, and (b) with respect to any additional Registration
Statements that may be required pursuant to Sections 2(a) and (b) hereof, the earlier of: (i) the 120th day following
the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement is required
under such Sections or

 

    	Appendix D-1

    	 

    

 

(ii)
the fifth trading day following the date on which the Company is notified by the Commission that such additional Registration
Statement will not be reviewed or is no longer subject to further review and comments. “Effectiveness Date”
shall also have the meaning specified in Section 2(b).

 

“Effectiveness
Period” shall have the meaning set forth in Section 2(a).

 

“Exchange
Act” means the Securities Exchange Act of 1934.

 

“Filing
Date” means: (a) with respect to the initial Registration Statement required to be filed to cover the resale by the
Holders of the Registrable Securities, the 90th day following the final Closing Date, and (b) with respect to any additional Registration
Statements that may be required pursuant to Sections 2(a) and (b) hereof, the 90th day following the date on which
the Company first knows, or reasonably should have known, that such additional Registration Statement is required under such Sections.

 

“Holder”
or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

 

“Indemnified
Party” shall have the meaning set forth in Section 5(c).

 

“Indemnifying
Party” shall have the meaning set forth in Section 5(c).

 

“Losses”
shall have the meaning set forth in Section 5(a).

 

“Notes”
means the convertible promissory notes included in a Unit that the Company is issuing to the Purchasers pursuant to the terms
of the Subscription Agreement that are convertible into the Company’s Common Stock and EdgePoint’s Common Stock

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding,
such as a deposition), whether commenced or threatened.

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering
of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by
reference in such Prospectus.

 

“Registrable
Securities” means the shares of EdgePoint Common Stock included in a Unit, the Warrants included in a Unit and the shares
of EdgePoint Common Stock and the Company’s Common Stock that may be issued upon conversion of the Notes and exercise of
the Warrants included in a Unit together with any securities issued or issuable upon any stock split, dividend or other distribution,
recapitalization or similar event, or any Note conversion rate or Warrant exercise price adjustment with respect thereto.

 

    	Appendix D-2

    	 

    

 

“Registration
Statement” means each of the following: (i) an initial registration statement which is required to register the resale
of the Registrable Securities, and (ii) each additional registration statement, if any, contemplated by Sections 2(a) and
(b), and including, in each case, the Prospectus, amendments and supplements to each such registration statement or Prospectus,
including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be
incorporated by reference in such registration statement.

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Rule
415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933.

 

“Selling
Stockholders” shall have meaning defined in Section 3(b)(iii).

 

“Transfer
Agent” means the transfer agent for the Company’s Common Stock and EdgePoint’s’ Common Stock, as the
case may be.

 

“Transaction
Documents” means this Agreement, the Subscription Agreement, the Warrants, and any other documents or agreements executed
in connection with the transactions contemplated hereunder and in the Subscription Agreement.

 

“Unit”
means a unit consisting of the Notes, 250,000 shares of EdgePoint Common Stock, the Company Warrants and the EdgePoint Warrants.

 

“Warrants”
means an aggregate 50,000 Company Warrants each to acquire one share of Company Common Stock at an exercise price of $0.20 and
an aggregate 50,000 EdgePoint Warrants each to acquire one EdgePoint share of Common Stock at an exercise price of $1.00 subject
to applicable anti dilution provisions set forth in the Warrants.

 

2.
Registration.

 

(a)
Initial Registration Statements. On or prior to each Filing Date, the Company shall prepare and file with the Commission
a Registration Statement covering the resale of all Registrable Securities not already covered by an existing and effective Registration
Statement for an offering to be made on a continuous basis pursuant to Rule 415. The Registration Statement shall be on Form S-1,
or another appropriate form for such purpose, and shall contain (except if otherwise required pursuant to written comments received
from the Commission upon a review of such Registration Statement) the “Plan of Distribution” attached hereto as Annex
A. The Company shall cause the Registration Statement to be declared effective under the Securities Act as soon as possible
but, in any event, no later than the Effectiveness Date, and shall use its reasonable best efforts to keep the Registration Statement
continuously effective under the Securities Act until the date that is two years after the date that the Registration Statement
is declared effective by the Commission or such earlier date when all Registrable Securities covered by the Registration Statement
have been sold or may be sold pursuant to Rule 144(b)(i) as determined by the counsel to the Company pursuant to a written opinion
letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders (the “Effectiveness Period”).
It is agreed and understood that the Company shall, from time to time, be obligated to file an additional Registration Statement
to cover any Registrable Securities that are not registered for resale pursuant to a pre-existing Registration Statement.

 

    	Appendix D-3

    	 

    

 

(b)
Additional Registration Statements. If for any reason the Commission does not permit all of the Registrable Securities
to be included in the Registration Statement filed pursuant to Section 2(a), then the Company shall prepare and file as
soon as possible after the date on which the Commission shall indicate as being the first date or time that such filing may be
made, but in any event by the 90th day following such date, an additional Registration Statement covering the resale of all Registrable
Securities not already covered by an existing and effective Registration Statement for an offering to be made on a continuous
basis pursuant to Rule 415, on Form S-1 or another appropriate form for such purpose. Each such Registration Statement shall contain
(except if otherwise required pursuant to written comments received from the Commission upon a review of such Registration Statement)
the “Plan of Distribution” attached hereto as Annex A. The Company shall cause each such Registration Statement
to be declared effective under the Securities Act as soon as possible (the “Effectiveness Date”) and shall
use its reasonable best efforts to keep such Registration Statement continuously effective under the Securities Act during the
entire Effectiveness Period.

 

(c)
Issuance of Legal Opinion.

 

(i)
Within three business days after the Effectiveness Date of a Registration Statement, the Company shall cause its counsel to issue
a blanket opinion in the form attached hereto as Exhibit A-1 or Exhibit A-2, as the case may be, (the “Form
Opinion”), to the Transfer Agent stating that the Shares, as defined therein, are subject to an effective registration
statement and can be reissued free of restrictive legend upon notice of a sale by the Purchaser and confirmation by the Purchaser
that it has complied with the prospectus delivery requirements, provided that the Company has not advised the Transfer Agent in
writing that the opinion has been withdrawn. Copies of the blanket opinion required by this Section 2(c) shall be delivered
to the Purchasers within the time period set forth above.

 

(ii)
In connection with Section 2(c)(i), the Company shall obtain confirmation from any new Transfer Agent, as may be engaged by the
Company from time to time, that the Form Opinion shall be sufficient to cause the removal of restrictive legends from the Shares
(as defined in the Form Opinion) and the Company shall provide confirmation of the same to the Purchasers.

 

3.
Registration Procedures. In connection with the Company’s registration obligations hereunder, the Company shall:

 

    	Appendix D-4

    	 

    

 

(a)
Not less than four trading days prior to the filing of a Registration Statement or any related Prospectus or any amendment or
supplement thereto, furnish to the Holders copies of all such documents proposed to be filed, which documents (other than those
incorporated by reference) will be subject to review by such Holders. The Company shall not file a Registration Statement or any
such Prospectus or any amendments or supplements thereto to which the Holders of a majority of the Registrable Securities shall,
in writing, reasonably object in good faith.

 

(b)
(i) Prepare and file with the Commission such amendments, including post- effective amendments, to each Registration Statement
and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective
as to the applicable Registrable Securities for its Effectiveness Period and prepare and file with the Commission such additional
Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii) cause
the related Prospectus to be amended or supplemented by any required Prospectus supplement, and as so supplemented or amended
to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably possible, and in any event within ten trading days,
to any comments received from the Commission with respect to each Registration Statement or any amendment thereto and, as promptly
as reasonably possible, provide the Holders true and complete copies of all correspondence from and to the Commission relating
to such Registration Statement that pertains to the Holders as selling stockholders (the “Selling Stockholders”)
but not any comments that would result in the disclosure to the Holders of material and non-public information concerning the
Company; and (iv) comply in all material respects with the provisions of the Securities Act and the Exchange Act with respect
to the Registration Statements and the disposition of all Registrable Securities covered by each Registration Statement.

 

(c)
Notify the Holders as promptly as reasonably possible (and, in the case of (i)(A) below, not less than three trading days prior
to such filing) and (if requested by any such Holder) confirm such notice in writing no later than one trading day following the
day (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed
to be filed; (B) when the Commission notifies the Company whether there will be a “review” of such Registration Statement
and whenever the Commission comments in writing on such Registration Statement (the Company shall provide true and complete copies
thereof and all written responses thereto to each of the Holders that pertain to such Holder as a Selling Stockholder or to the
Plan of Distribution, but not information which the Company believes would constitute material and non-public information); and
(C) with respect to each Registration Statement or any post-effective amendment, when the same has become effective; (ii) of any
request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration
Statement or Prospectus or for additional information that pertains to the Holders as Selling Stockholders or the Plan of Distribution;
(iii) of the issuance by the Commission of any stop order suspending the effectiveness of a Registration Statement covering any
or all of the Registrable Securities or the initiation of any Proceedings for that purpose; (iv) of the receipt by the Company
of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable
Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose; and (v) of the occurrence
of any event or condition that makes the financial statements included in a Registration Statement ineligible for inclusion therein
or any statement made in such Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein
by reference untrue in any material respect or that requires any revisions to such Registration Statement, Prospectus or other
documents so that, in the case of such Registration Statement or the Prospectus, as the case may be, it will not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading.

 

    	Appendix D-5

    	 

    

 

(d)
Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the
effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any
of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

 

(e)
Furnish to each Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto
and all exhibits to the extent requested by such Holder (including those previously furnished or incorporated by reference) promptly
after the filing of such documents with the Commission; provided, however, that the Company shall have no obligation
to provide any document pursuant to this clause that is available on the EDGAR system.

 

(f)
Promptly deliver to each Holder, without charge, as many copies of each Prospectus or Prospectuses (including each form of prospectus)
and each amendment or supplement thereto as such Holder may reasonably request. The Company hereby consents to the use of such
Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of
the Registrable Securities covered by such Prospectus and any amendment or supplement thereto.

 

(g)
Prior to any public offering of Registrable Securities, use its reasonable best efforts to register or qualify or cooperate with
the selling Holders in connection with the registration or qualification (or exemption from such registration or qualification)
of such Registrable Securities for offer and sale under the securities or Blue Sky laws of those jurisdictions within the United
States set forth on Schedule 3(g) hereto to keep each such registration or qualification (or exemption therefrom) effective
during the Effectiveness Period and to do any and all other acts or things necessary or advisable to enable the disposition in
such jurisdictions of the Registrable Securities covered by the Registration Statements; provided, however, that
neither the Company nor EdgePoint shall be required to qualify generally to do business in any jurisdiction where it is not then
so qualified or subject the Company or EdgePoint to any material tax in any such jurisdiction where it is not then so subject
or to take such actions in states that require merit review.

 

(h)
Cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Registrable Securities
to be delivered to a transferee pursuant to the Registration Statements, which certificates shall be free, to the extent permitted
by the Subscription Agreement and applicable law, of all restrictive legends, and to enable such Registrable Securities to be
in such denominations and registered in such names as any such Holders may request. The Company shall cause the Transfer Agent
to transmit the Registrable Securities to the Holder by crediting the account of the Holder’s prime broker with the Depository
Trust Company through its Deposit Withdrawal Agent Commission system if the Company is then a participant in such system.

 

    	Appendix D-6

    	 

    

 

(i)
Upon the occurrence of any event contemplated by Section 3(c)(v), as promptly as reasonably possible, prepare a supplement
or amendment, including a post-effective amendment, to the affected Registration Statements or a supplement to the related Prospectus
or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that,
as thereafter delivered, no Registration Statement nor any Prospectus will contain an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading.

 

The
Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock
beneficially owned by such Holder and any Affiliate thereof.

 

4.
Registration Expenses. All fees and expenses incident to the Company’s performance of its obligation under this Agreement
(excluding any underwriting discounts and selling commissions and all legal fees and expenses of legal counsel for any Holder)
shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees
and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including,
without limitation, fees and expenses (A) with respect to filings required to be made with the trading market on which the Common
Stock is then listed for trading, if any, and (B) in compliance with applicable state securities or Blue Sky laws), (ii) printing
expenses (including, without limitation, expenses of printing certificates for Registrable Securities and of printing prospectuses
if the printing of prospectuses is reasonably requested by the holders of a majority of the Registrable Securities included in
the Registration Statement), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the
Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other
Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition,
the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions
contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing
legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing
of the Registrable Securities on any securities exchange as required hereunder.

 

    	Appendix D-7

    	 

    

 

5.
Indemnification.

 

(a) Indemnification
by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each
Holder, the officers, directors, agents, attorneys, investment advisors, partners, members, shareholders and employees of
each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act) and the officers, directors, agents, attorneys and employees of each such controlling Person, to the
fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs
(including, without limitation, reasonable costs of preparation and reasonable attorneys’ fees) and expenses
(collectively, “Losses”), as incurred, arising out of or relating to any untrue or alleged untrue
statement of a material fact contained in any Registration Statement, any Prospectus or any form of prospectus or in any
amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or
in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required
to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or
supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent, but only
to the extent, that (1) such untrue statements or omissions are based solely upon information regarding such Holder furnished
in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such
Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly
approved in writing by such Holder expressly for use in the Registration Statement, such Prospectus or such form of
Prospectus or in any amendment or supplement thereto (it being understood that each Holder has approved Annex A hereto
for this purpose) or (2) in the case of an occurrence of an event of the type specified in Section 3(c)(ii)-(v), the
use by such Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the
Prospectus is outdated or defective and prior to the receipt by such Holder of an Advice, as defined in Section 6(c) below,
or an amended or supplemented Prospectus, but only if and to the extent that following the receipt of the Advice or the
amended or supplemented Prospectus the misstatement or omission giving rise to such Loss would have been corrected. The
Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding of which the Company is
aware in connection with the transactions contemplated by this Agreement.

 

(b)
Indemnification by Holders. Each Holder shall, notwithstanding any termination of this Agreement, severally and not jointly,
indemnify and hold harmless the Company and EdgePoint, its directors, officers, agents, attorneys and employees, each Person who
controls the Company and EdgePoint, as the case may be (within the meaning of Section 15 of the Securities Act and Section 20
of the Exchange Act), and the directors, officers, agents, attorneys or employees of such controlling Persons, to the fullest
extent permitted by applicable law, from and against all Losses, as incurred, arising solely out of or based solely upon: (x)
such Holder’s failure to comply with the prospectus delivery requirements of the Securities Act or (y) any untrue statement
of a material fact contained in any Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or
supplement thereto, or arising solely out of or based solely upon any omission of a material fact required to be stated therein
or necessary to make the statements therein not misleading to the extent, but only to the extent that, (1) such untrue statements
or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly
for use therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution
of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in the Registration
Statement (it being understood that each Holder has approved Annex A hereto for this purpose), such Prospectus or such
form of Prospectus or in any amendment or supplement thereto or (2) in the case of an occurrence of an event of the type specified
in Section 3(c)(ii)-(v), the use by such Holder of an outdated or defective Prospectus after the Company has notified such
Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of an Advice or an amended
or supplemented Prospectus, but only if and to the extent that following the receipt of the Advice or the amended or supplemented
Prospectus the misstatement or omission giving rise to such Loss would have been corrected. In no event shall the liability of
any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the
sale of the Registrable Securities giving rise to such indemnification obligation.

 

    	Appendix D-8

    	 

    

 

(c)
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity
is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall assume the defense thereof,
including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses
incurred in connection with defense thereof; provided, however, that the failure of any Indemnified Party to give such
notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only)
to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to
appeal or further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party.

 

An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying
Party has agreed in writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed promptly to assume the
defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or
(3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying
Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely to exist if the same
counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies
the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying
Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Indemnifying Party);
provided, however, that the Indemnifying Party shall not be liable for the fees and expenses of more than one separate firm of
attorneys at any time for all Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding
effected without its written consent, which consent shall not be unreasonably withheld. No Indemnifying Party shall, without the
prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified
Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims
that are the subject matter of such Proceeding.

 

All
fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating
or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party,
as incurred, within ten trading days of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately
determined that an Indemnified Party is not entitled to indemnification hereunder; provided, however, that the Indemnifying
Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially
determined that such Indemnified Party is not entitled to indemnification hereunder).

 

(d)
Contribution. If a claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified
Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party,
shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is
appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements
or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying
Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or
made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount
paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in Section
5(c), any reasonable attorneys’ or other reasonable fees or expenses incurred by such party in connection with any Proceeding
to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section
was available to such party in accordance with its terms.

 

    	Appendix D-9

    	 

    

 

The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined
by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred
to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required
to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Holder from
the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise
been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.

 

The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties
may have to the Indemnified Parties.

 

6.
Miscellaneous

 

(a)
Remedies. In the event of a breach by the Company or by a Holder, of any of their obligations under this Agreement, each
Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this
Agreement, including recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company
and each Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach
by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance
in respect of such breach, it shall waive the defense that a remedy at law would be adequate.

 

(b)
Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities
Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement.

 

(c)
Discontinued Disposition. Each Holder agrees by its acquisition of such Registrable Securities that, upon receipt of a
notice from the Company of the occurrence of any event of the kind described in Section 3(c), such Holder will forthwith
discontinue disposition of such Registrable Securities under the Registration Statement until such Holder’s receipt of the
copies of the supplemented Prospectus and/or amended Registration Statement or until it is advised in writing (the “Advice”)
by the Company that the use of the applicable Prospectus may be resumed, and, in either case, has received copies of any additional
or supplemental filings that are incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement.
The Company may provide appropriate stop orders to enforce the provisions of this paragraph.

 

    	Appendix D-10

    	 

    

 

(d)
Amendments and Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed by
the Company and the Holder or Holders (as applicable) of no less than a majority of the then outstanding Registrable Securities.
No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such
right.

 

(e)
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication
is delivered via electronic transmission at the or email address specified in this Section prior to 5:00 p.m. (California time)
on a Business Day, (ii) the Business Day after the date of transmission, if such notice or communication is delivered via electronic
transmission at the email address specified in this Agreement later than 5:00 p.m. (California time) on any date and earlier than
11:59 p.m. (California time) on such date, (iii) the Business Day following the date of dispatch, if sent by nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for
such notices and communications shall be as follows:

 

If
to the Company:

 

Mateon
Therapeutics, Inc. 29397 Agoura Road

Suite
107

Agoura
Hills, CA 91301 Telephone:(650) 635-7002

Email
Address: ashah@oncotelic.com (with a copy to vtrieu@oncotelic.com)

	 	Attention:	Amit
    Shah, CFO
	 	 	 
	 	If
    to a Purchaser:	To
    the address set forth under such Purchaser’s name on the signature pages hereto.

 

If
to any other Person who is then the registered Holder:

 

To
the address of such Holder as it appears in the stock transfer books of the Company or such other address as may be designated
in writing hereafter, in the same manner, by such Person.

 

(f)
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties and shall inure to the benefit of each Holder. The Company may not assign its rights or obligations hereunder
without the prior written consent of each Holder. Holders may assign their respective rights hereunder in the manner and to the
Persons as permitted under the Subscription Agreement.

 

(g)
Execution and Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed
shall be deemed to be an original and, all of which taken together shall constitute one and the same Agreement. In the event that
any signature is delivered by facsimile or electronic transmission, such signature shall create a valid binding obligation of
the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile
or electronic signature were the original thereof.

 

    	Appendix D-11

    	 

    

 

(h)
Governing Law; Venue. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard
to the principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective Affiliates,
employees or agents) may be commenced in the state and federal courts sitting in Orange County, California. Each party hereto
hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a
copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in
effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way the right of a party to bring any action or proceeding
against another party or its property in the courts of any other jurisdiction or the right of a party to serve process in any
manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and
all right to trial by jury in any Proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
If any party shall commence a Proceeding to enforce any provisions of this Agreement, then the prevailing party in such Proceeding
shall be reimbursed by the other party for its attorney’s fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Proceeding.

 

(i)
Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.

 

(j)
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that
contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the
parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such
that may be hereafter declared invalid, illegal, void or unenforceable.

 

(k)
Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect
the meaning hereof.

 

(l)
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser hereunder are several
and not joint with the obligations of any other Purchaser hereunder, and no Purchaser shall be responsible in any way for the
performance of the obligations of any other Purchaser hereunder. The decision of each Purchaser to purchase Units and/or Underlying
Securities pursuant to the Transaction Documents has been made independently of any other Purchaser. Nothing contained herein
or in any other agreement or document delivered at any closing, and no action taken by any Purchaser pursuant hereto or thereto,
shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or
create a presumption that the Purchasers are in any way acting in concert with respect to such obligations or the transactions
contemplated by this Agreement. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection
with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring
its investment in the Units and/or Underlying Securities or enforcing its rights under the Transaction Documents. Each Purchaser
shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and
it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.

 

(m)
Gender. The use herein of the masculine pronouns or similar terms shall be deemed to include the feminine and neuter genders
as well and vice versa and the use of the singular pronouns shall be deemed to include the plural as well and vice versa.

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGES TO FOLLOW]

 

    	Appendix D-12

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

 

	 	MATEON
    THERAPEUTICS, INC.
	 	 	 
	 	By:	 
	 	Name:	Vuong
    Trieu
	 	Title:	Chief
    Executive Officer

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE
PAGES OF PURCHASER TO FOLLOW]

 

    	Appendix D-13

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

 

_________________________

 

By:
_____________________________________________

 

Name:
___________________________________________

 

Title:____________________________________________

 

Address
for Notice:

_______________________

_______________________

_______________________

 

Email
Address:_____________________________

 

Attn.:_____________________________________

 

With
a copy to:

__________________________________________

__________________________________________

__________________________________________

 

Email
Address:______________________________

 

Attn:
______________________________________

 

    	Appendix D-14

    	 

    

 

ANNEX
A

J.H.
Darbie & Co., Inc. Plan of Distribution for Mateon Private Placement

 

J.H.
Darbie & Co., Inc. (“JHD”) is the distributor for this Private Placement in Mateon Therapeutics. This Regulation
D 506(c) offering is made to accredited investors and up to 35 non-accredited invetors. The offering is sold by private placement
memorandum, and all investors must meet the following criteia:

 

	 	●	received
    the private placement memorandum
	 	 	 
	 	●	complete
    a subcription agreement
	 	 	 
	 	●	registration
    rights offering

 

JHD
is under no obligation to purchase units of this offering and makes no guarantee the minimum number of units will be sold. The
private placement documents describe the investment minimums and timing of the first closing.

 

We
or our agents may solicit offers to purchase units on a best efforts basis for the period of its appointment.

 

In
connection with the sale of this offering JHD may receive compensation as described in the private placement agreeement and memorandum.

 

JHD
may invite other broker-dealers to participate in the distribution of this offering. Any other broker- dealer invited must be
approved by the issuer and will require appropriate amendments and diclosures to the accompanying offering documents and placement
agreement. Such dealers, may receive compensation in the form of discounts, concessions, or commissions from purchasers for whom
they may act as agents. We will identify any such dealer or agent, and we will describe any compensation paid to them in the related
private placement documents.

 

JHD
is obligated to sell A minimum of 40 units to close this private placement and may discontinue any sales activity at any time,
without prior notice. If 40 units cannot be sold, all funds will be returned to investors without financial penalty to them. Additionally,
the representatives of JHD may determine not to engage in selling transactions or that those transactions, once commenced, may
be discontinued without notice.

 

In
no event will the commission or discount received by JHD exceed fifteen percent of the aggregate principal amount of the offering
of these units of this private placement.

 

    	Appendix D-15

    	 

    

 

EXHIBIT
A-1

_______________________,
202_

 

American
Stock Transfer & Trust Company, LLC (AST)

 

Re:
Mateon Therapeutics, Inc.

 

Ladies
and Gentlemen:

 

As
counsel to Mateon Therapeutics, Inc., a Delaware corporation (the “Company”), we have been requested to consider
whether the legend referencing the registration requirements of the Securities Act of 1933(the “Act”), may
be removed from [•] shares (the “Shares”) of the Company’s common stock, par value $0.01 per share
(the “Common Stock”), held in book-entry form and consisting of [•] shares of Common Stock issued to [•]
and [•] Warrants (the “Warrants”) each exercisable to purchase [•] shares of the Company’s
common stock, held in book-entry form and consisting of [•] Warrants issued to [•].

 

The
Shares and Warrants were registered on a Registration Statement on Form [•] (File No. 333-[•]), initially filed by the
Company with the Securities and Exchange Commission (the “SEC”) on [•] (the “Registration Statement”)
and the related Prospectus dated [•] (as further supplemented from time to time, the “Resale Prospectus”)
relating to an aggregate of [•] shares (the “PIPE Shares”) of the Company’s Common Stock and Warrants
issued or to be issued to [•] and the other selling stockholders (together with [•], the “Selling Stockholders”)
identified in the Resale Prospectus. The Registration Statement registers the PIPE Shares and Warrants for resale by the Selling
Stockholders and was declared effective by the SEC on [•] at 4:30

p.m.
Eastern Time. We have no knowledge that any stop order suspending its effectiveness has been issued or that any proceedings for
that purpose are pending before, or threatened by, the SEC.

 

For
purposes of our opinion below, we have relied on the representations made by [•] in a representation letter dated as of [•]
and attached hereto as Exhibit A-1.

 

We
have assumed the genuineness of all signatures, the legal capacity of all individual signatories, the authenticity of all documents
submitted to us as originals, the conformity to original documents of documents submitted to us as certified or photostatic copies,
and the authenticity of such latter documents.

 

Based
upon the foregoing (including compliance with the representations referred to above), we are of the opinion that the restrictive
legend may be removed from the Shares.

 

Very
truly yours,

 

__________________________

__________________________

__________________________

 

    	Appendix D-16

    	 

    

 

EXHIBIT
A-2

______________________,
202_

 

American
Stock Transfer & Trust Company, LLC (AST)

 

Re:
EdgePoint AI, Inc.

 

Ladies
and Gentlemen:

 

As
counsel to EdgePoint AI, Inc., a Delaware corporation (the “Company”), we have been requested to consider whether
the legend referencing the registration requirements of the Securities Act of 1933(the “Act”), may be removed
from [•] shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common
Stock”), held in book- entry form and consisting of [•] shares of Common Stock issued to [•]and [•] Warrants
(the “Warrants”) each exercisable to purchase [•] shares of the Company’s common stock, held in
book-entry form and consisting of [•] Warrants issued to [•]..

 

The
Shares and Warrants were registered on a Registration Statement on Form [•] (File No. 333-[•]), initially filed by the
Company with the Securities and Exchange Commission (the “SEC”) on [•] (the “Registration Statement”)
and the related Prospectus dated [•] (as further supplemented from time to time, the “Resale Prospectus”)
relating to an aggregate of [•] shares (the “PIPE Shares”) of the Company’s Common Stock and Warrants
issued or to be issued to [•] and the other selling stockholders (together with [•], the “Selling Stockholders”)
identified in the Resale Prospectus. The Registration Statement registers the PIPE Shares and Warrants for resale by the Selling
Stockholders and was declared effective by the SEC on [•] at 4:30

p.m.
Eastern Time. We have no knowledge that any stop order suspending its effectiveness has been issued or that any proceedings for
that purpose are pending before, or threatened by, the SEC.

 

For
purposes of our opinion below, we have relied on the representations made by [•] in a representation letter dated as of [•]
and attached hereto as Exhibit A-2.

 

We
have assumed the genuineness of all signatures, the legal capacity of all individual signatories, the authenticity of all documents
submitted to us as originals, the conformity to original documents of documents submitted to us as certified or photostatic copies,
and the authenticity of such latter documents.

 

Based
upon the foregoing (including compliance with the representations referred to above), we are of the opinion that the restrictive
legend may be removed from the Shares.

 

Very
truly yours,

 

________________________

________________________

________________________

 

    	Appendix D-17

    	 

    

 

SCHEDULE
3(g)

 

BLUE
SKY JURISDICTIONS

AND/OR

STATES
OF SOLICITAION

 

ALL
STATES

 

    	Appendix D-18dtil-ex101_19.htm

Exhibit 10.1

 

THIRD AMENDMENT TO LEASE 

THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of the _15th_ day of June, 2020 (the “Effective Date”), by and between DURHAM TW ALEXANDER, LLC, a Delaware limited liability company (“Landlord”), and PRECISION BIOSCIENCES, INC., a Delaware corporation (formerly a North Carolina corporation) (“Tenant”). 

STATEMENT OF PURPOSE

WHEREAS, Landlord and Tenant entered into that certain Lease dated October 2, 2018 (“Initial Lease”) as amended by that certain First Amendment to Lease dated December 23, 2019 (“First Amendment”) and as further amended by that certain Second Amendment to Lease dated March 13, 2020 (“Second Amendment”) (as amended, the “Existing Lease”), for certain premises containing approximately 33,828 rentable square feet on the first (1st) floor (the “Premises”) located in the building known as Biopoint Innovation Labs located at 20 TW Alexander Drive, Research Triangle Park, North Carolina 27709 (the “Building”), as more particularly described in the Lease. 

WHEREAS, Landlord and Tenant desire to amend the terms of the Existing Lease: (i) to extend the date by which Tenant must utilize the Tenant Improvements Allowance, as defined in the First Amendment, and (ii) to modify certain other terms of the Existing Lease.  For purposes hereof, the Lease as amended by this Amendment is referred to as the “Lease.”  All capitalized terms not otherwise defined herein shall have the meanings set forth in the Existing Lease.

NOW, THEREFORE, in consideration of the statement of purpose, the mutual covenants contained herein and other valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows:

	
 
	
1.
	
Recitals.  The recitals shall form a part of this Amendment.

2.Extension of the Tenant Improvements Allowance Disbursement Deadline.  Due to various delays in the performance of the Tenant Improvements, as defined in the First Amendment, Landlord and Tenant hereby agree that the deadline for Tenant to request disbursements from the Tenant Improvement Allowance under Section 2.2 of Exhibit C of the First Amendment shall be extended until June 30, 2021.  For purposes of clarity, Landlord also hereby acknowledges and agrees that Tenant’s delayed occupancy of the Premises and construction timeline does not constitute abandonment under Section 19.1.3 of the Lease. 

3.Counterparts/Signatures.  This Amendment may be executed in counterparts.  All executed counterparts shall constitute one agreement, and each counterpart shall be deemed an original.  The parties hereby acknowledge and agree that electronic signatures, facsimile signatures or signatures transmitted by electronic mail in so-called “pdf” format shall be legal and binding and shall have the same full force and effect as if an original of this Amendment had been delivered.  Landlord and Tenant (i) intend to be bound by the signatures (whether original, faxed or electronic) on any document sent by facsimile or electronic mail, (ii) are aware that the other party will rely on such signatures, and (iii) hereby waive any defenses to the enforcement of the terms of this Amendment based on the foregoing forms of signature.

 

 

Exhibit 10.1

 

4.Miscellaneous.  This Amendment shall become effective only upon full execution and delivery of this Amendment by Landlord and Tenant.  This Amendment contains the parties’ entire agreement regarding the subject matter covered by this Amendment, and supersedes all prior correspondence, negotiations, and agreements, if any, whether oral or written, between the parties concerning such subject matter.  There are no contemporaneous oral agreements, and there are no representations or warranties between the parties not contained in this Amendment.  This Amendment shall be construed and enforced in accordance with the laws of the State of North Carolina.  Except as modified by this Amendment, the terms and provisions of the Lease shall remain in full force and effect, and the Lease, as modified by this Amendment, shall be binding upon and shall inure to the benefit of the parties hereto, their successors and permitted assigns.

[Signature Page Follows]

[The remainder of this page has been intentionally left blank]

 

 

Exhibit 10.1

 

LANDLORD AND TENANT enter into this Amendment as of the Effective Date above.

LANDLORD:

DURHAM TW ALEXANDER, LLC,

a Delaware limited liability company

By: /s/ Jamison Peschel
Name: Jamison Peschel
Title: Authorized Signatory

 

TENANT:

PRECISION BIOSCIENCES, INC.,

a Delaware corporation

By: /s/ Sinu Bhandaru
Name: Sinu Bhandaru
Title: VP Operations & IT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]